2023

Glial Fibrillary Acidic Protein (GFAP)
GFAP is a biomarker for Traumatic Brain Injury (TBI). It can reach high concentrations in TBI, resulting in physical, cognitive, social, emotional, and behavioral symptoms. Outcomes can range from complete recovery to permanent disability or death.
Read more
2022

Interleukin-6
Interleukin-6 is a biomarker for acute inflammation and it can reach high concentrations in case of sepsis, a life-threatening condition triggered by infection. Therefore, IL-6 is an important marker for early diagnosis and monitoring of sepsis.
Read more
2022

First Distributed Testing Event
In SensUs 2020 and 2021, both offline SensUs Events were held online due to the coronavirus pandemic. The teams really enjoyed participating in this manner at their own universities. Now that the event can continue offline, the SensUs Organization has launched a new initiative called the Distributed Testing Event. This event allows the teams to prepare for the Eindhoven Testing Event under real competition conditions.
Read more
2021

Hemagglutinin
The theme of SensUs 2021 was acute respiratory viruses. The Covid-19 pandemic made it apparent that large virus outbreaks can cause immense harm to human health and can disrupt society as a whole. One of the most common respiratory viruses is influenza A. Biosensors for the detection of influenza A could help to prevent the spread of this virus.
Read more
2020

Valproate
Valproate (VPA) is a drug used in the treatment of epilepsy, bipolar disorder and spinal muscular atrophy. Epilepsy affects around 50 million people worldwide. A biosensor for the measurement of VPA could help to the quality of life by personalizing VPA treatment.
Read more
2020

First Online SensUs Innovation Days
Unfortunately, due to the coronavirus pandemic, the SensUs Innovation Days could not be organized physically in Eindhoven. However, the show must go on! That is why the SensUs Organization arranged the Innovation Days to be held in a virtual environment.
Read more
2019

Adalimumab
SensUs 2019 challenged student teams to develop innovative biosensing systems for the measurement of adalimumab, a biological drug that is prescribed to patients suffering from rheumatoid arthritis (RA). RA affects around 1% of the world population. Measurement of adalimumab concentrations will enable more efficient and effective management of the disease.
Read more
2018

Vancomycin
SensUs 2018 challenged student teams to develop innovative biosensing systems for the measurement of the antibiotic drug vancomycin. Antibiotic drugs are widely used in society. Unfortunately, the massive use of drugs causes Anti-Microbial Resistance (AMR). On a personal level, a vancomycin biosensor could help to provide patients with the right dose, thereby increasing the effectiveness and reducing the side effects of drug treatment.
Read more
2017

NT-probNP
Heart failure (HF) is a very important public health problem in both developed and developing countries with a prevalence of about 1% of the population. In 2017 SensUs featured NT-proBNP as its target molecule, which is a key biomarker for heart failure.
Read more
2016

Creatinine
SensUs 2016 was all about biosensors for kidney failure detection. Creatinine is a waste molecule that is filtered out of the blood by the kidneys. By detecting this molecule, patients can take control of their health by monitoring their kidneys fast and easy.
Read more